{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:28:29Z","timestamp":1793831309181,"version":"4.6.1"},"reference-count":145,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kisupplements.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Supplements"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.kisu.2021.11.002","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T05:02:55Z","timestamp":1647579775000},"page":"36-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["The renin\u2013angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0792-6239","authenticated-orcid":false,"given":"Carlos M.","family":"Ferrario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Groban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"VonCannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra N.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarfaraz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kisu.2021.11.002_bib1","series-title":"Life of Galileo","author":"Brecht","year":"1994"},{"key":"10.1016\/j.kisu.2021.11.002_bib2","doi-asserted-by":"crossref","first-page":"(S1):1","DOI":"10.1096\/fasebj.2020.34.s1.09150","article-title":"Human angiotensin-(1-12) [Ang-(1-12)] is a hypertension and cardiac disease biomarker","volume":"34","author":"Ferrario","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.kisu.2021.11.002_bib3","doi-asserted-by":"crossref","unstructured":"Hollenberg MD, Epstein M. The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets. Kidney Int Suppl. 2022;12:48\u201362.","DOI":"10.1016\/j.kisu.2021.12.001"},{"key":"10.1016\/j.kisu.2021.11.002_bib4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1042\/CS20130400","article-title":"An evolving story of angiotensin-II-forming pathways in rodents and humans","volume":"126","author":"Ferrario","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.kisu.2021.11.002_bib5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.002_bib6","first-page":"949","article-title":"Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations","volume":"33","author":"Leoncini","year":"2020","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.kisu.2021.11.002_bib7","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1097\/HJH.0000000000000380","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk\u2014overview and meta-analyses of randomized trials","volume":"32","author":"Thomopoulos","year":"2014","journal-title":"J\u00a0Hypertens"},{"issue":"suppl 1","key":"10.1016\/j.kisu.2021.11.002_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11739-011-0669-5","article-title":"The epidemiological concept of residual risk","volume":"6","author":"Vanuzzo","year":"2011","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.kisu.2021.11.002_bib9","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/00004872-200106000-00021","article-title":"Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group","volume":"19","author":"Zanchetti","year":"2001","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kisu.2021.11.002_bib10","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.116.303641","article-title":"Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal","volume":"116","author":"Zanchetti","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.kisu.2021.11.002_bib11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1161\/01.CIR.101.4.446","article-title":"Essential hypertension : part II: treatment","volume":"101","author":"Carretero","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2021.11.002_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11906-017-0708-3","article-title":"Novel cardiac intracrine mechanisms based on Ang-(1-12)\/chymase axis require a revision of therapeutic approaches in human heart disease","volume":"19","author":"Reyes","year":"2017","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.kisu.2021.11.002_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijcard.2014.11.179","article-title":"Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: a number-needed-to-treat analysis","volume":"181","author":"Brugts","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.kisu.2021.11.002_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1753944716644131","article-title":"Mega clinical trials which have shaped the RAS intervention clinical practice","volume":"10","author":"Dusing","year":"2016","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.kisu.2021.11.002_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1753944716644130","article-title":"Pharmacological interventions into the renin-angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering","volume":"10","author":"Dusing","year":"2016","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.kisu.2021.11.002_bib16","doi-asserted-by":"crossref","first-page":"111119","DOI":"10.1016\/j.mce.2020.111119","article-title":"The angiotensin-(1-12)\/chymase axis as an alternate component of the tissue renin angiotensin system","volume":"529","author":"Ferrario","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.kisu.2021.11.002_bib17","series-title":"Singh AK and Williams GH, eds. Textbook of Nephro-Endocrinology","first-page":"179","article-title":"The renin angiotensin system and the heart","author":"Trask","year":"2018"},{"key":"10.1016\/j.kisu.2021.11.002_bib18","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2021.11.002_bib19","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1093\/eurheartj\/ehn427","article-title":"Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials","volume":"29","author":"Turnbull","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kisu.2021.11.002_bib20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kisu.2021.11.002_bib21","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.002_bib22","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kisu.2021.11.002_bib23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.peptides.2012.09.016","article-title":"Subcellular characteristics of functional intracellular renin-angiotensin systems","volume":"38","author":"Abadir","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.kisu.2021.11.002_bib24","doi-asserted-by":"crossref","first-page":"C995","DOI":"10.1152\/ajpcell.00238.2006","article-title":"Intracellular angiotensin II induces cell proliferation independent of AT1 receptor","volume":"291","author":"Baker","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.kisu.2021.11.002_bib25","doi-asserted-by":"crossref","first-page":"H766","DOI":"10.1152\/ajpheart.00632.2017","article-title":"Role of intracellular angiotensin II","volume":"314","author":"Re","year":"2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.kisu.2021.11.002_bib26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/CIRCRESAHA.117.310978","article-title":"Multifunctional role of chymase in acute and chronic tissue injury and remodeling","volume":"122","author":"Dell'Italia","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.kisu.2021.11.002_bib27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0005-2744(79)90056-1","article-title":"Isolation of completely inactive plasma prorenin and its activation by kallikreins. A possible new link between renin and kallikrein","volume":"569","author":"Yokosawa","year":"1979","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.kisu.2021.11.002_bib28","doi-asserted-by":"crossref","unstructured":"Ryan JW. The fate of angiotensin II. In: Page IH, Bumpus FM (eds). Angiotensin. Handbuch der experimentellen Pharmakologie \/ Handbook of Experimental Pharmacology, vol 37. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-642-65600-2_4","DOI":"10.1007\/978-3-642-65600-2_4"},{"key":"10.1016\/j.kisu.2021.11.002_bib29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/01.HYP.0000196268.08909.fb","article-title":"Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation","volume":"47","author":"Ferrario","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.002_bib30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1161\/HYPERTENSIONAHA.109.145839","article-title":"New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism","volume":"55","author":"Ferrario","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.002_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MNH.0b013e3283406f57","article-title":"ACE2: more of Ang-(1-7) or less Ang II?","volume":"20","author":"Ferrario","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kisu.2021.11.002_bib32","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.2174\/1381612811319170012","article-title":"Non-ACE pathway-induced angiotensin II production","volume":"19","author":"Uehara","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.kisu.2021.11.002_bib33","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1152\/ajpregu.00535.2002","article-title":"The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction","volume":"285","author":"Schmaier","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.kisu.2021.11.002_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1126\/science.95.2456.101","article-title":"\u201cPepsitensin\u201d\u2014a hypertensinlike substance produced by peptic digestion of proteins","volume":"95","author":"Croxatto","year":"1942","journal-title":"Science"},{"key":"10.1016\/j.kisu.2021.11.002_bib35","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/01.hjh.0000242404.91332.be","article-title":"Renal cathepsin G and angiotensin II generation","volume":"24","author":"Rykl","year":"2006","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kisu.2021.11.002_bib36","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM197909273011320","article-title":"Glandular kallikrein","volume":"301","author":"Sealey","year":"1979","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.002_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/01.RES.41.4.26","article-title":"Tonin, angiotensin II system. A review","volume":"41","author":"Boucher","year":"1977","journal-title":"Circ Res"},{"key":"10.1016\/j.kisu.2021.11.002_bib38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1042\/CS20130449","article-title":"Recent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system","volume":"127","author":"Ocaranza","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.kisu.2021.11.002_bib39","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/01.HYP.0000205833.89478.5b","article-title":"Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II","volume":"47","author":"Yamamoto","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.002_bib40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1042\/CS20200163","article-title":"Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?","volume":"134","author":"Batlle","year":"2020","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.kisu.2021.11.002_bib41","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1161\/HYPERTENSIONAHA.120.15256","article-title":"Interaction of SARS-CoV-2 and other coronavirus with ACE (angiotensin-converting enzyme)-2 as their main receptor: therapeutic implications","volume":"76","author":"Davidson","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.002_bib42","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1042\/CS20200901","article-title":"Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease","volume":"134","author":"Ferrario","year":"2020","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.kisu.2021.11.002_bib43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem J"},{"key":"10.1016\/j.kisu.2021.11.002_bib44","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0196-9781(93)90097-Z","article-title":"Cardiovascular actions of angiotensin(1-7)","volume":"14","author":"Benter","year":"1993","journal-title":"Peptides"},{"key":"10.1016\/j.kisu.2021.11.002_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0895-7061(97)00400-7","article-title":"Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects","volume":"11","author":"Ferrario","year":"1998","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.kisu.2021.11.002_bib46","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/00004872-199606000-00017","article-title":"Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension","volume":"14","author":"Luque","year":"1996","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kisu.2021.11.002_bib47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/01.HYP.30.3.535","article-title":"Counterregulatory actions of angiotensin-(1-7)","volume":"30","author":"Ferrario","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.002_bib48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.regpep.2012.04.004","article-title":"Angiotensin-(3-4) counteracts the angiotensin II inhibitory action on renal Ca2+-ATPase through a cAMP\/PKA pathway","volume":"177","author":"Axelband","year":"2012","journal-title":"Regul Pept"},{"key":"10.1016\/j.kisu.2021.11.002_bib49","article-title":"Is angiotensin-(3-4) (Val-Tyr), the shortest angiotensin II-derived peptide, opening new vistas on the renin-angiotensin system?","volume":"18","author":"Dias","year":"2017","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.kisu.2021.11.002_bib50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.ne.03.030180.001303","article-title":"Substance P as a transmitter candidate","volume":"3","author":"Nicoll","year":"1980","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.kisu.2021.11.002_bib51","first-page":"H1769","article-title":"Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations","volume":"273","author":"Balcells","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.kisu.2021.11.002_bib52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.regpep.2004.04.004","article-title":"Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy","volume":"120","author":"Baker","year":"2004","journal-title":"Regul Pept"},{"key":"10.1016\/j.kisu.2021.11.002_bib53","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1042\/CS20120089","article-title":"The intracrine renin-angiotensin system","volume":"123","author":"Kumar","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.kisu.2021.11.002_bib54","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCRESAHA.113.301077","article-title":"Discovery and characterization of alamandine: a novel component of the renin-angiotensin system","volume":"112","author":"Lautner","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.kisu.2021.11.002_bib55","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/01.ATV.0000253889.09765.5f","article-title":"Mass-spectrometric identification of a novel angiotensin peptide in human plasma","volume":"27","author":"Jankowski","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kisu.2021.11.002_bib56","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology","volume":"98","author":"Forrester","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1016\/j.kisu.2021.11.002_bib57","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1124\/pr.113.008136","article-title":"MAS and its related G protein-coupled receptors","volume":"66","author":"Bader","year":"2014","journal-title":"Mrgprs. Pharmacol Rev"},{"key":"10.1016\/j.kisu.2021.11.002_bib58","doi-asserted-by":"crossref","first-page":"H137","DOI":"10.1152\/ajpheart.00618.2015","article-title":"Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?","volume":"310","author":"Chappell","year":"2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.kisu.2021.11.002_bib59","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/0024-3205(93)90108-F","article-title":"A\u00a0comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11","volume":"52","author":"Welches","year":"1993","journal-title":"Life Sci"},{"key":"10.1016\/j.kisu.2021.11.002_bib60","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00004872-199107000-00008","article-title":"Evidence that prolyl endopeptidase participates in the processing of brain angiotensin","volume":"9","author":"Welches","year":"1991","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kisu.2021.11.002_bib61","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/biom9080382","article-title":"Thimet oligopeptidase (EC 3.4.24.15) key functions suggested by knockout mice phenotype characterization","volume":"9","author":"Santos","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.kisu.2021.11.002_bib62","series-title":"Proceedings of a Satellite to the Seventh Scientific Meeting of the International Society of Hypertension","article-title":"Heterogeneity of renin and renin-substrate","author":"Sambhi","year":"1981"},{"key":"10.1016\/j.kisu.2021.11.002_bib63","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ajh\/2.5.411","article-title":"Immunochemical comparison of high molecular weight angiotensinogen from amniotic fluid, plasma of men, and plasma of pregnant women","volume":"2","author":"Tewksbury","year":"1989","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.kisu.2021.11.002_bib64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0009-8981(86)90110-5","article-title":"High molecular weight angiotensinogen: a pregnancy associated protein","volume":"158","author":"Tewksbury","year":"1986","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.kisu.2021.11.002_bib65","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3181\/00379727-153-39536","article-title":"Heterogeneity of renin substrate in human plasma: effect of pregnancy and oral contraceptives","volume":"153","author":"Gordon","year":"1976","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.kisu.2021.11.002_bib66","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.bbrc.2006.09.146","article-title":"Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system","volume":"350","author":"Nagata","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.kisu.2021.11.002_bib67","doi-asserted-by":"crossref","first-page":"H2242","DOI":"10.1152\/ajpheart.00175.2008","article-title":"Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart","volume":"294","author":"Trask","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.kisu.2021.11.002_bib68","doi-asserted-by":"crossref","first-page":"H644","DOI":"10.1152\/ajpheart.00210.2013","article-title":"Primacy of angiotensin converting enzyme in angiotensin-(1-12) metabolism","volume":"305","author":"Moniwa","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.kisu.2021.11.002_bib69","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/13543776.2018.1531848","article-title":"Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018)","volume":"28","author":"Ahmad","year":"2018","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.kisu.2021.11.002_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028501","article-title":"Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue","volume":"6","author":"Ahmad","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2021.11.002_bib71","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11906-014-0429-9","article-title":"Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate","volume":"16","author":"Ahmad","year":"2014","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.kisu.2021.11.002_bib72","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1152\/ajpregu.90588.2008","article-title":"Chronic immunoneutralization of brain angiotensin-(1-12) lowers blood pressure in transgenic (mRen2)27 hypertensive rats","volume":"297","author":"Isa","year":"2009","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.kisu.2021.11.002_bib73","doi-asserted-by":"crossref","first-page":"H763","DOI":"10.1152\/ajpheart.00345.2010","article-title":"Angiotensin-(1-12) requires angiotensin converting enzyme and AT1 receptors for cardiovascular actions within the solitary tract nucleus","volume":"299","author":"Arnold","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.kisu.2021.11.002_bib74","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.autneu.2012.10.016","article-title":"Role of the hypothalamic arcuate nucleus in cardiovascular regulation","volume":"175","author":"Sapru","year":"2013","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.kisu.2021.11.002_bib75","doi-asserted-by":"crossref","first-page":"H2614","DOI":"10.1152\/ajpheart.91521.2007","article-title":"Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats","volume":"294","author":"Jessup","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.kisu.2021.11.002_bib76","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fcvm.2019.00163","article-title":"Activation of the human angiotensin-(1-12)-chymase pathway in rats with human angiotensinogen gene transcripts","volume":"6","author":"Ferrario","year":"2019","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.kisu.2021.11.002_bib77","doi-asserted-by":"crossref","first-page":"H995","DOI":"10.1152\/ajpheart.00833.2015","article-title":"Cardiac angiotensin-(1-12) expression and systemic hypertension in rats expressing the human angiotensinogen gene","volume":"310","author":"Ferrario","year":"2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.kisu.2021.11.002_bib78","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11010-016-2801-3","article-title":"Intracellular angiotensin-(1-12) changes the electrical properties of intact cardiac muscle","volume":"422","author":"De Mello","year":"2016","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.kisu.2021.11.002_bib79","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2019.09.052","article-title":"Angiotensin-(1-12)\/chymase axis modulates cardiomyocyte L-type calcium currents in rats expressing human angiotensinogen","volume":"297","author":"Reyes","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.kisu.2021.11.002_bib80","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.119.13754","article-title":"Noncanonical mechanisms for direct bone marrow generating Ang II (angiotensin II) predominate in CD68 positive myeloid lineage cells","volume":"75","author":"Yamashita","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.002_bib81","doi-asserted-by":"crossref","first-page":"111256","DOI":"10.1016\/j.mce.2021.111256","article-title":"Newly developed radioimmunoassay for human angiotensin-(1-12) measurements in plasma and urine","volume":"529","author":"Ahmad","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.kisu.2021.11.002_bib82","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1161\/HYPERTENSIONAHA.120.16514","article-title":"Angiotensin (1-12) in humans with normal blood pressure and primary hypertension","volume":"77","author":"Ferrario","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.002_bib83","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.bbrc.2013.10.124","article-title":"Big angiotensin-25: a novel glycosylated angiotensin-related peptide isolated from human urine","volume":"441","author":"Nagata","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.kisu.2021.11.002_bib84","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/nep.13845","article-title":"Development of a novel AlphaLISA immunoassay for big angiotensin-25","volume":"26","author":"Nagata","year":"2021","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.kisu.2021.11.002_bib85","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/jcp.26179","article-title":"Blunting of estrogen modulation of cardiac cellular chymase\/RAS activity and function in SHR","volume":"233","author":"Ahmad","year":"2018","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.kisu.2021.11.002_bib86","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.freeradbiomed.2019.01.029","article-title":"Plasma xanthine oxidase activity is related to increased sodium and left ventricular hypertrophy in resistant hypertension","volume":"134","author":"Butts","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.kisu.2021.11.002_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2019.e01397","article-title":"Chymase uptake by cardiomyocytes results in myosin degradation in cardiac volume overload","volume":"5","author":"Powell","year":"2019","journal-title":"Heliyon"},{"key":"10.1016\/j.kisu.2021.11.002_bib88","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/10641963.2021.1890762","article-title":"Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal haemodynamics, and excretion in spontaneously hypertensive rats","volume":"43","author":"Roszkowska-Chojecka","year":"2021","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.kisu.2021.11.002_bib89","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1113\/EP087209","article-title":"Effects of the selective chymase inhibitor TEI-F00806 on the intrarenal renin-angiotensin system in salt-treated angiotensin I-infused hypertensive mice","volume":"103","author":"Ansary","year":"2018","journal-title":"Exp Physiol"},{"key":"10.1016\/j.kisu.2021.11.002_bib90","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1021\/bi00798a004","article-title":"Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis","volume":"10","author":"Ondetti","year":"1971","journal-title":"Biochemistry"},{"key":"10.1016\/j.kisu.2021.11.002_bib91","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jch.12032","article-title":"Randomized study of antihypertensive efficacy and safety of combination aliskiren\/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus","volume":"15","author":"Bakris","year":"2013","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.kisu.2021.11.002_bib92","first-page":"459","article-title":"Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors","volume":"5","author":"Pimenta","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.kisu.2021.11.002_bib93","series-title":"Angiotensin II Receptor Antagonists","author":"Epstein","year":"2001"},{"key":"10.1016\/j.kisu.2021.11.002_bib94","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/HYPERTENSIONAHA.119.13437","article-title":"Future of hypertension","volume":"74","author":"Dzau","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.002_bib95","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0167-0115(93)90438-E","article-title":"Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin","volume":"49","author":"Gyurko","year":"1993","journal-title":"Regul Pept"},{"key":"10.1016\/j.kisu.2021.11.002_bib96","first-page":"2661","article-title":"Immunologic approaches to the inhibition of renin and the adrenergic system","volume":"42","author":"Haber","year":"1983","journal-title":"Fed Proc"},{"key":"10.1016\/j.kisu.2021.11.002_bib97","first-page":"1193","article-title":"Inhibitors of renin: present and future","volume":"5","author":"Haber","year":"1983","journal-title":"Clin Exp Hypertens A"},{"key":"10.1016\/j.kisu.2021.11.002_bib98","first-page":"3155","article-title":"Peptide inhibitors of renin in cardiovascular studies","volume":"42","author":"Haber","year":"1983","journal-title":"Fed Proc"},{"key":"10.1016\/j.kisu.2021.11.002_bib99","first-page":"1207","article-title":"Antibodies as specific renin inhibitors: studies with polyclonal and monoclonal antibodies and Fab fragments","volume":"5","author":"Dzau","year":"1983","journal-title":"Clin Exp Hypertens A"},{"key":"10.1016\/j.kisu.2021.11.002_bib100","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1210\/endo-120-6-2334","article-title":"A\u00a0comparative study of the distributions of renin and angiotensinogen messenger ribonucleic acids in rat and mouse tissues","volume":"120","author":"Dzau","year":"1987","journal-title":"Endocrinology"},{"key":"10.1016\/j.kisu.2021.11.002_bib101","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/01.CIR.81.6.1899","article-title":"Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin","volume":"81","author":"Michel","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2021.11.002_bib102","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.117.09755","article-title":"Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury","volume":"70","author":"Mullick","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.002_bib103","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","article-title":"Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen","volume":"73","author":"Uijl","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.002_bib104","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1042\/CS20201239","article-title":"No evidence for brain renin-angiotensin system activation during DOCA-salt hypertension","volume":"135","author":"Uijl","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.kisu.2021.11.002_bib105","doi-asserted-by":"crossref","first-page":"A15555","DOI":"10.1161\/circ.142.suppl_3.15555","article-title":"Abstract 15555: potential cure for hypertension? The effect of Crispr genome editing","volume":"142","author":"Sun","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2021.11.002_bib106","article-title":"Antisense oligonucleotides targeting angiotensinogen: insights from animal studies","volume":"39","author":"Wu","year":"2019","journal-title":"Biosci Rep"},{"key":"10.1016\/j.kisu.2021.11.002_bib107","doi-asserted-by":"crossref","first-page":"A14387","DOI":"10.1161\/circ.142.suppl_3.14387","article-title":"Abstract 14387: Dose-related reductions in blood pressure with a RNA interference (RNAi) therapeutic targeting angiotensinogen in hypertensive patients: interim results from a first-in-human phase 1 study of ALN-AGT01","volume":"142","author":"Huang","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2021.11.002_bib108","doi-asserted-by":"crossref","first-page":"7943","DOI":"10.1128\/JVI.00549-10","article-title":"A\u00a0single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets","volume":"84","author":"Bodewes","year":"2010","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.kisu.2021.11.002_bib109","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jim.2016.09.008","article-title":"CoVaccine HT adjuvant is superior to Freund's adjuvants in eliciting antibodies against the endogenous alarmin HMGB1","volume":"439","author":"Lakhan","year":"2016","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.kisu.2021.11.002_bib110","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(08)60381-5","article-title":"Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study","volume":"371","author":"Tissot","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2021.11.002_bib111","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clim.2009.06.003","article-title":"Immunization against angiotensins for the treatment of hypertension","volume":"134","author":"Maurer","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.kisu.2021.11.002_bib112","first-page":"269","article-title":"CYT-006-AngQb, a vaccine against angiotensin II for the potential treatment of hypertension","volume":"10","author":"Phisitkul","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.kisu.2021.11.002_bib113","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0167-0115(95)00104-J","article-title":"In\u00a0vivo applications of antisense oligonucleotides for peptide research","volume":"59","author":"Phillips","year":"1995","journal-title":"Regul Pept"},{"key":"10.1016\/j.kisu.2021.11.002_bib114","first-page":"51","article-title":"Antisense therapeutics for hypertension: targeting the renin-angiotensin system","volume":"106","author":"Phillips","year":"2005","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.kisu.2021.11.002_bib115","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1042\/CS20210163","article-title":"Letter to the editor: brain renin-angiotensin system and liver-directed siRNA targeted to angiotensinogen","volume":"135","author":"Ferrario","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.kisu.2021.11.002_bib116","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1073\/pnas.80.8.2196","article-title":"Cloning and sequence analysis of cDNA for rat angiotensinogen","volume":"80","author":"Ohkubo","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kisu.2021.11.002_bib117","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/hr.2016.17","article-title":"Structure and functions of angiotensinogen","volume":"39","author":"Lu","year":"2016","journal-title":"Hypertens Res"},{"key":"10.1016\/j.kisu.2021.11.002_bib118","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/hr.2016.106","article-title":"Corrigendum: structure and functions of angiotensinogen","volume":"39","author":"Lu","year":"2016","journal-title":"Hypertens Res"},{"key":"10.1016\/j.kisu.2021.11.002_bib119","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/ATVBAHA.115.306740","article-title":"Angiotensinogen exerts effects independent of angiotensin II","volume":"36","author":"Lu","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kisu.2021.11.002_bib120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ymthe.2006.01.017","article-title":"Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen","volume":"14","author":"Bouquet","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.kisu.2021.11.002_bib121","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/hy0202.103441","article-title":"Angiotensinogen and its cleaved derivatives inhibit angiogenesis","volume":"39","author":"Celerier","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.002_bib122","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11906-003-0072-3","article-title":"Inhibition of angiogenesis: a new function for angiotensinogen and des(angiotensin I)angiotensinogen","volume":"5","author":"Corvol","year":"2003","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.kisu.2021.11.002_bib123","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1158\/0008-5472.CAN-08-2484","article-title":"Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice","volume":"69","author":"Vincent","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.kisu.2021.11.002_bib124","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/2070","article-title":"Impaired blood-brain barrier function in angiotensinogen-deficient mice","volume":"4","author":"Kakinuma","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.kisu.2021.11.002_bib125","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1210\/endo.142.12.8556","article-title":"Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity","volume":"142","author":"Massiera","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.kisu.2021.11.002_bib126","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2310\/JIM.0b013e31827c28bb","article-title":"Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy","volume":"61","author":"Kobori","year":"2013","journal-title":"J\u00a0Investig Med"},{"key":"10.1016\/j.kisu.2021.11.002_bib127","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1097\/HJH.0b013e3283392673","article-title":"Urinary angiotensinogen is correlated with blood pressure in men (Bogalusa Heart Study)","volume":"28","author":"Kobori","year":"2010","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kisu.2021.11.002_bib128","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/01.mnh.0000436544.86508.f1","article-title":"Intrarenal renin-angiotensin system in regulation of glomerular function","volume":"23","author":"Navar","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kisu.2021.11.002_bib129","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2021.11.002_bib130","first-page":"24","article-title":"ACE inhibitors and ARBs: one or the other\u2014not both\u2014for high-risk patients","volume":"58","author":"Misra","year":"2009","journal-title":"J\u00a0Fam Pract"},{"key":"10.1016\/j.kisu.2021.11.002_bib131","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2125.2003.01926.x","article-title":"Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man","volume":"56","author":"Downham","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.kisu.2021.11.002_bib132","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HJH.0b013e32800ff5d6","article-title":"A\u00a0vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity","volume":"25","author":"Ambuhl","year":"2007","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kisu.2021.11.002_bib133","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/HJH.0000000000002597","article-title":"A\u00a0novel angiotensin II peptide vaccine without an adjuvant in mice","volume":"39","author":"Nakamaru","year":"2021","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kisu.2021.11.002_bib134","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1253\/circj.CJ-20-0703","article-title":"Future directions of therapeutic vaccines for chronic diseases","volume":"84","author":"Nakamaru","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.kisu.2021.11.002_bib135","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00281-014-0425-9","article-title":"Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases","volume":"36","author":"Wallukat","year":"2014","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.kisu.2021.11.002_bib136","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1056\/NEJMoa035717","article-title":"Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection","volume":"352","author":"Dragun","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.002_bib137","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/HYPERTENSIONAHA.112.202945","article-title":"Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of aldosterone-producing adenoma","volume":"61","author":"Rossitto","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.002_bib138","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","article-title":"Monoclonal antibody therapy of cancer","volume":"23","author":"Adams","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.kisu.2021.11.002_bib139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J\u00a0Biomed Sci"},{"key":"10.1016\/j.kisu.2021.11.002_bib140","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2165\/00003495-200464220-00004","article-title":"Prevention of type 2 diabetes mellitus through inhibition\u00a0of the renin-angiotensin system","volume":"64","author":"Scheen","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.kisu.2021.11.002_bib141","first-page":"108","article-title":"Effects of ACE inhibitors and calcium antagonists on progression of chronic renal disease","volume":"2","author":"Epstein","year":"1995","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.kisu.2021.11.002_bib142","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/ncpneph0980","article-title":"Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease","volume":"5","author":"Epstein","year":"2009","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.kisu.2021.11.002_bib143","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/euhj.1999.1740","article-title":"Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure","volume":"21","author":"Roig","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kisu.2021.11.002_bib144","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1021\/acschemneuro.9b00217","article-title":"Single domain antibody fragments as new tools for the detection of neuronal Tau protein in cells and in mice studies","volume":"10","author":"Dupre","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.kisu.2021.11.002_bib145","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/anie.201708459","article-title":"Nanobodies: chemical functionalization strategies and intracellular applications","volume":"57","author":"Schumacher","year":"2018","journal-title":"Angew Chem Int Ed Engl"}],"container-title":["Kidney International Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171621000654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171621000654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:52:21Z","timestamp":1775004741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2157171621000654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":145,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2157171621000654"],"URL":"https:\/\/doi.org\/10.1016\/j.kisu.2021.11.002","relation":{},"ISSN":["2157-1716"],"issn-type":[{"value":"2157-1716","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The renin\u2013angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts","name":"articletitle","label":"Article Title"},{"value":"Kidney International Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2021.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}